|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1995-3-9
|
|
pubmed:abstractText |
A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1182674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1346171,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1363199,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1397246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1486035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1531068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1536941,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1922221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-1970939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-2104241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-2184356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-2210687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-2571812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-2571813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-3115884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-3593657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-3717812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-6546971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-7039824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-7459811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7841049-7505124
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
326-30
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7841049-Adult,
pubmed-meshheading:7841049-Aged,
pubmed-meshheading:7841049-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7841049-Bone Marrow Transplantation,
pubmed-meshheading:7841049-Dexamethasone,
pubmed-meshheading:7841049-Doxorubicin,
pubmed-meshheading:7841049-Female,
pubmed-meshheading:7841049-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:7841049-Humans,
pubmed-meshheading:7841049-Male,
pubmed-meshheading:7841049-Middle Aged,
pubmed-meshheading:7841049-Multiple Myeloma,
pubmed-meshheading:7841049-Remission Induction,
pubmed-meshheading:7841049-Survival Analysis,
pubmed-meshheading:7841049-Vincristine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
VAD chemotherapy as remission induction for multiple myeloma.
|
|
pubmed:affiliation |
Department of Medical Oncology, Christie Hospital, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article
|
